HomeMYCOD • OTCMKTS
add
Mydecine Innovations Group Inc
Nakaraang pagsara
$0.096
Sakop ng taon
$0.0050 - $0.45
Market cap
284.06K CAD
Average na Volume
583.00
P/E ratio
-
Dividend yield
-
Primary exchange
CNSX
Mga balita tungkol sa merkado
Times Colonist
2 araw ang nakalipas
Tech stocks weigh on Canadian, U.S. markets while pot stocks surge
0.42%
Mga Financial
Income Statement
Kita
Net na kita
| (CAD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | -110.70K | -106.77% |
Net na kita | 73.79K | 103.71% |
Net profit margin | — | — |
Kita sa bawat share | — | — |
EBITDA | — | — |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (CAD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 47.08K | -21.76% |
Kabuuang asset | 47.08K | -73.60% |
Kabuuang sagutin | 15.21M | -13.71% |
Kabuuang equity | -15.16M | — |
Natitirang share | 1.24M | — |
Presyo para makapag-book | -0.01 | — |
Return on assets | 1,169.87% | — |
Return on capital | -3.35% | — |
Cash Flow
Net change in cash
| (CAD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 73.79K | 103.71% |
Cash mula sa mga operasyon | 46.85K | -5.49% |
Cash mula sa pag-invest | — | — |
Cash mula sa financing | — | — |
Net change in cash | 46.85K | -5.49% |
Malayang cash flow | 43.36K | -88.85% |
Tungkol
Mydecine Innovations Group, or simply Mydecine, is an American and Canadian pharmaceutical company that is developing psychedelics and entactogens as medicines.
In August 2022, it was reported that Mydecine was experiencing financial difficulties and might cease operations. However, the company was able to obtain more funding and did not shutdown. Mydecine made the first legal import of magic mushrooms into Canada in 2021.
Mydecine's drug candidates include the psychedelics psilocybin, MYCO-004, and MYCO-005 and the novel MDMA-like entactogens MYCO-002, MYCO-006, and MYCO-007.
Although the chemical structures of most of its drug candidates have not been disclosed, Mydecine has patented 5-BZT-MDMA and 6-BZT-MDMA as short-acting MDMA analogues. Wikipedia
Itinatag
2013
Headquarters
Website
Mga Empleyado
3
